Last10K.com

Aemetis, Inc (AMTX) SEC Filing 10-Q Quarterly Report for the period ending Wednesday, March 31, 2021

Aemetis, Inc

CIK: 738214 Ticker: AMTX
  Exhibit 99.1
External Investor Relations Contact:
Kirin Smith
PCG Advisory Group
(646) 863-6519
ksmith@pcgadvisory.com
 
Company Contact:
                                                                 Todd Waltz
                                                                 Chief Financial Officer
                                                                 (408) 213-0925
                                                                 twaltz@aemetis.com
 
 
Aemetis Reports 2020 Fourth Quarter and Year-End Results
 
CUPERTINO, Calif. – March 11, 2021 –
Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on below zero carbon intensity products, today announced its financial results for the three and twelve months ended December 31, 2020.
 
“Despite historic economic disruptions that significantly reduced gasoline and ethanol demand, revenues for ethanol production in 2020 were relatively flat compared to 2019 largely due to our ability to quickly pivot to alternative markets and establish new revenue streams,” said Eric McAfee, Chairman and CEO of Aemetis. “Ethanol and high grade alcohol revenues in 2020 were $112 million compared to $115 million in 2019, Gross Profit percentage margins improved by approximately 6%, SG&A expenses were reduced, and Earnings per Share was largely unchanged from 2019 to 2020 as higher margin businesses largely offset the adverse impact of the COVID-19 pandemic,” added McAfee.
 
“Overall, this earnings report was a positive outcome for 2020, a year in which more than 50 ethanol plants were shut down at various times due to gasoline demand decreases and corn price increases, while the Aemetis plant operated continuously throughout the year. During this same time, we upgraded production equipment to supply high grade alcohol into the sanitizer alcohol market,” McAfee stated.
 
“We focused on keeping a safe working environment for our employees and on building carbon intensity reduction projects that grew value for shareholders significantly through $17 million of investment in low carbon intensity capital projects during 2020 despite the difficult external conditions. We completed Phase I of the dairy Renewable Natural Gas project, began installation of important Keyes ethanol plant system upgrades to significantly reduce carbon intensity, and began operations of the Messer CO2 liquification facility that is now generating CO2 revenues and IRS 45Q credits from carbon re-use.”
 
“We also made major steps toward receiving the Authority to Construct air permit for the Aemetis “Carbon Zero” integrated biorefinery in Riverbank, California. The Carbon Zero project is designed to further optimize the economics of the Keyes plant by using the 142-acre Riverbank site to build a plant to utilize distillers corn oil from the Keyes ethanol plant along with below-zero carbon intensity Cellulosic Hydrogen from waste orchard wood to produce Renewable Jet and Diesel,” said McAfee.
 
“We are excited with the progress made during the many challenges we faced in 2020, and thank our employees for their focus, hard work, and ability to transition to new markets. We look forward to building on this success in 2021 as we complete additional important milestones in dairy RNG, Renewable Jet and Diesel Fuel, India biodiesel government contracts, and Ethanol margin improvements from carbon intensity reduction, and continue to implement the Five Year Plan we announced in early March,” McAfee stated.
 
 
 
 
Today, Aemetis will host an earnings review call at 11:00 a.m. Pacific time (PT).
 
Live Participant Dial In (Toll Free): +1-888-506-0062 entry code 823496
Live Participant Dial In (International): +1-973-528-0011 entry code 823496
Webcast URL:  https://www.webcaster4.com/Webcast/Page/2211/40258
 
For the presentation and details on the call, please visit http://www.aemetis.com/investors/conference-calls/
 
Financial Results for the Three Months Ended December 31, 2020
 
Revenues were $37.3 million for the fourth quarter of 2020, compared to $52.1 million for the fourth quarter of 2019. The decrease in revenue was primarily attributable to delays in the India government Oil Marketing Company biodiesel tender process that delayed revenue in our India operations, and temporarily lower ethanol production in North America due to the lack of enforcement of the 15 billion gallon Renewable Fuel Standard ethanol blending mandate by the EPA.
 
Gross loss for the three months ended December 31, 2020 was $3.4 million, compared to a gross profit of $5.8 million during the same period in 2019. The gross profit change was attributable to the temporary ethanol production volume reduction during Q4 2020 due to the price of ethanol decrease from $1.82 per gallon during the three months ended December 31, 2019 to $1.64 per gallon during the three months ended December 31, 2020 in a market where the cost of delivered corn rose from $5.02 to $5.61 per bushel during the same respective periods.
 
Selling, general and administrative expenses decreased to $4.3 million during the fourth quarter of 2020, compared to $4.7 million during the fourth quarter of 2019.
 
Operating loss was $7.7 million for the fourth quarter of 2020, compared to operating income of $1.0 million during the fourth quarter of 2019.
 
Net loss was $14.6 million for the fourth quarter of 2020, compared to a net loss of $7.7 million for the fourth quarter of 2019.
 
Cash at the end of the fourth quarter of 2020 was $592 thousand, compared to $656 thousand at the end of the fourth quarter of 2019.
 
Financial Results for the Twelve Months Ended December 31, 2020
 
Revenues were $166 million for the twelve months ended December 31, 2020, compared to $202 million for the same period in 2019. The decrease in revenue was primarily attributable to decreases in the production and sales price for ethanol in North America caused by the COVID pandemic and oil refinery blending waivers issued by the EPA, and delays in the Oil Marketing Company tender process for the India biodiesel operations.
 
Gross profit for the twelve months ended December 31, 2020 was $11.0 million, compared to $12.7 million of gross profit during the same period in 2019, despite lower demand for gasoline and ethanol during 2020 due to the COVID-19 pandemic. Compared to 2019, US domestic ethanol demand declined by 13%, and US ethanol exports declined by 5% in 2020. For the same period, the delivered price of corn to the Keyes plant increased by 11%. The gross profit decline from ethanol margin reduction was largely offset by sales into the sanitizer alcohol market.
 
Selling, general and administrative expenses decreased to $16.9 million during the twelve months ended December 31, 2020, compared to $17.4 million during the same period in 2019.
 
 
 
 
Operating loss increased to $6.1 million for the twelve months ended December 31, 2020, compared to an operating loss of $4.9 million for the same period in 2019.
 
Net loss was $36.7 million for the twelve months ended December 31, 2020, a 7% improvement compared to a net loss of $39.5 million during the same period in 2019.
 
About Aemetis
 
Headquartered in Cupertino, California, Aemetis is a renewable natural gas, renewable fuel and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace carbon-based products and reduce greenhouse gas emissions. Founded in 2006, Aemetis has completed Phase 1 and is expanding a California biogas digester network and pipeline system to convert dairy waste gas into Renewable Natural Gas (RNG). Aemetis owns and operates a 65 million gallon per year ethanol production facility in California’s Central Valley near Modesto that supplies about 80 dairies with animal feed. Aemetis also owns and operates a 50 million gallon per year production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India and Europe. Aemetis is developing the Carbon Zero renewable jet and diesel fuel integrated biorefineries in California to utilize distillers corn oil from ethanol plants to produce low carbon intensity renewable jet and diesel fuel using cellulosic hydrogen from waste orchard wood and other negative carbon intensity biomass, and pre-extract cellulosic sugars from the waste biomass to be processed into high value cellulosic ethanol at the Keyes plant. Aemetis holds a portfolio of patents and related technology licenses for the production of renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com.
 
Safe Harbor Statement
 
This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, expectations regarding development of our waste wood ethanol and biogas businesses in North America.  Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “showing signs,” “targets,” “view,” “will likely result,” “will continue” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, and other risks detailed in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2020 and in our subsequent filings with the SEC. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.
 (Tables follow)
 
 
 
 
AEMETIS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(In thousands, except per share data, unaudited)
 
 
 
Three months ended
 
 
Year ended
 
 
 
December 31,
 
 
December 31,
 
 
 
2020
 
 
2019
 
 
2020
 
 
2019
 
Revenues
 $37,330 
 $52,102 
 $165,557 
 $201,998 
Cost of goods sold
  40,702 
  46,308 
  154,532 
  189,300 
Gross profit (loss)
  (3,372)
  5,794 
  11,025 
  12,698 
 
    
    
    
    
Research and development expenses
  38 
  45 
  213 
  205 
Selling, general and administrative expenses
  4,334 
  4,709 
  16,882 
  17,424 
Operating profit (loss)
  (7,744)
  1,040 
  (6,070)
  (4,931)
 
    
    
    
    
Interest rate expense
  5,987 
  5,517 
  22,943 
  21,089 
Amortization expense
  823 
  1,101 
  3,401 
  4,666 
Accretion of Series A preferred
  586 
  748 
  4,673 
  2,257 
Loss contingency on litigation
 
 
 
 
 
 
  6,200 
Other expense/(income)
  155 
  204 
  548 
  (797)
Loss before income taxes
  (15,295)
  (6,530)
  (37,635)
  (38,346)
 
    
    
    
    
Income tax expense (benefit)
  (713)
  1,124 
  (976)
  1,131 
 
    
    
    
    
Net loss
 $(14,582)
 $(7,654)
 $(36,659)
 $(39,477)
Non controlling interest
  - 
  (929)
  - 
  (3,761)
Net loss attributable to Aemetis
 $(14,582)
 $(6,725)
 $(36,659)
 $(35,716)
 
    
    
    
    
Net loss per common share
    
    
    
    
Basic
 $(0.67)
 $(0.33)
 $(1.74)
 $(1.75)
Diluted
 $(0.67)
 $(0.33)
 $(1.74)
 $(1.75)
 
    
    
    
    
Weighted average shares outstanding
    
    
    
    
Basic
  21,845 
  20,570 
  21,012 
  20,467 
Diluted
  21,845 
  20,570 
  21,012 
  20,467 
 
 
 
 
AEMETIS, INC.
CONSOLIDATED CONDENSED BALANCE SHEETS
(In thousands, unaudited)
 
 
 
Year ended December 31,
 
 
 
2020
 
 
2019
 
Assets
 
 
 
 
 
 
Current assets:
 
 
 
 
 
 
Cash and cash equivalents
 $592 
 $656 
Accounts receivable
  1,821 
  2,036 
Inventories
  3,969 
  6,518 
Prepaid and other current assets
  2,301 
  3,366 
Total current assets
  8,683 
  12,576 
 
    
    
Property, plant and equipment, net
  109,880 
  84,226 
Other assets
  6,576 
  3,094 
Total assets
 $125,139 
 $99,896 
 
    
    
Liabilities and stockholders' deficit
    
    
Current liabilities:
    
    
Accounts payable
 $20,739 
 $15,968 
Current portion of long term debt
  44,974 
  5,792 
Short term borrowings
  14,541 
  16,948 
Mandatorily redeemable Series B convertible preferred stock
  3,252 
  3,149 
Accrued property taxes and other liabilities
  18,729 
  15,962 
Total current liabilities
  102,235 
  57,819 
 
    
    
Total long term liabilities
  207,648 
  196,449 
 
    
    
Stockholders' deficit:
    
    
Series B convertible preferred stock
  1 
  1 
Common stock
  23 
  21 
Additional paid-in capital
  93,426 
  86,852 
Accumulated deficit
  (274,080)
  (237,421)
Accumulated other comprehensive loss
  (4,114)
  (3,825)
Total stockholders' deficit
  (184,744)
  (154,372)
Total liabilities and stockholders' deficit
 $125,139 
 $99,896 
 
 
 
 
RECONCILIATION OF ADJUSTED EBITDA TO NET INCOME / (LOSS)
(In thousands, unaudited)
 
 
 
Three months ended
December 31,
 
 
Year ended
December 31,
 
 
 
2020
 
 
2019
 
 
2020
 
 
2019
 
Net loss attributable to Aemetis, Inc.
 $(14,582)
 $(6,725)
 $(36,659)
 $(35,716)
Adjustments:
    
    
    
    
Interest expense
  6,810 
  5,800 
  26,344 
  22,420 
Depreciation expense
  1,379 
  1,097 
  4,894 
  4,434 
Accretion of Series A preferred
  586 
  748 
  4,673 
  2,257 
Share-based-compensation
  169 
  144 
  995 
  774 
Intangibles and other expense
  12 
  12 
  48 
  48 
Loss contingency on litigation
   - 
   - 
   - 
  6,200 
Income tax expense (benefit)
  (713)
  1,124 
  (976)
  1,131 
Total adjustments
  8,243 
  8,925 
  35,978 
  37,264 
Adjusted EBITDA
 $(6,339)
 $2,200 
 $(681)
 $1,548 
 
PRODUCTION AND PRICE PERFORMANCE
(unaudited)
 
 
 
Three months ended
 
 
Year ended
 
 
 
December 31,
 
 
December 31,
 
 
 
2020
 
 
2019
 
 
2020
 
 
2019
 
Ethanol and high grade alcohol
 
 
 
 
 
 
 
 
 
 
 
 
Gallons Sold (in millions)
  15.4 
  16.6 
  60.2 
  64.7 
Average Sales Price/Gallon
 $1.60 
 $1.82 
 $1.84 
 $1.77 
Percent of nameplate capacity
  112%
  120%
  112%
  118%
WDG
    
    
    
    
Tons Sold (in thousands)
  101 
  108 
  393 
  428 
Average Sales Price/Ton
 $90 
 $78 
 $81 
 $81 
Delivered Cost of Corn
    
    
    
    
Bushels ground (in millions)
  5.3 
  5.8 
  21.1 
  22.7 
Average delivered cost / bushel
 $5.61 
 $5.02 
 $5.05 
 $5.28 
Biodiesel
    
    
    
    
Metric tons sold (in thousands)
  1.7 
  11.9 
  16.0 
  47.0 
Average Sales Price/Metric ton
 $879 
 $861 
 $863 
 $904 
Percent of Nameplate Capacity
  5%
  32%
  10%
  31%
Refined Glycerin
    
    
    
    
Metric tons sold (in thousands)
  0.3 
  1.2 
  1.4 
  5.2 
Average Sales Price/Metric ton
 $803 
 $508 
 $814 
 $543 
 
 

The following information was filed by Aemetis, Inc (AMTX) on Thursday, March 11, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
———————
FORM 10-Q
———————
   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: March 31, 2021
OR
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             
Commission File Number: 001-36475
———————
AEMETIS, INC.
 (Exact name of registrant as specified in its charter)
———————
Nevada
26-1407544
(State or other jurisdiction
(I.R.S. Employer
of incorporation or organization)
Identification No.)
 
20400 Stevens Creek Blvd., Suite 700
Cupertino, CA 95014
 (Address of Principal Executive Offices, including zip code)
 
(408) 213-0940
 (Registrant’s telephone number, including area code)
 
Title of each class of registered securities
 
Trading Symbol
 
Name of each exchange on which registered
Common Stock, $0.001 par value
 
 
AMTX
 
NASDAQ
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes  ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes   No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ☐ Accelerated filer ☐  Non-accelerated filer ☐ Smaller reporting company ☑ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
The number of shares outstanding of the registrant’s Common Stock on April 30, 2021 was 31,414,465 shares.
 

 
 
 
 
AEMETIS, INC.
 
FORM 10-Q
 
Quarterly Period Ended March 31, 2021
 
INDEX
 
 
 
2
 
 
SPECIAL NOTE REGARDING FORWARD—LOOKING STATEMENTS
 
On one or more occasions, we may make forward-looking statements in this Quarterly Report on Form 10-Q, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this Quarterly Report on Form 10-Q include, without limitation, statements regarding management’s plans; trends in market conditions with respect to prices for inputs for our products versus prices for our products; our ability to leverage approved feedstock pathways; our ability to leverage our location and infrastructure; our ability to incorporate lower-cost, non-food advanced biofuels feedstock at the Keyes plant; our ability to adopt value-add by-product processing systems; our ability to expand into alternative markets for biodiesel and its by-products, including continuing to expand our sales into international markets; our ability to maintain and expand strategic relationships with suppliers; our ability to continue to develop new and to maintain and protect new and existing intellectual property rights; our ability to adopt, develop and commercialize new technologies; our ability to refinance our senior debt on terms reasonably acceptable to us or at all; our ability to continue to fund operations and our future sources of liquidity and capital resources; our ability to sell additional notes under our EB-5 note program and our expectations regarding the release of funds from escrow under our EB-5 note program; our ability to improve margins; and our ability to raise additional capital. Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “targets,” “will likely result,” “will continue” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, the risks set forth under the caption “Risk Factors” below, which are incorporated herein by reference as well as those business risks and factors described elsewhere in this report and in our other filings with the Securities and Exchange Commission (the “SEC”), including without limitation, our most recent Annual Report on Form 10-K.
 
 
3
 
 
PART I - FINANCIAL INFORMATION
 
Item 1 - Financial Statements.
 
AEMETIS, INC.
 
CONSOLIDATED CONDENSED BALANCE SHEETS
(In thousands except for par value)
 
 
 
March 31,
2021
 
 
December 31,
2020
 
Assets
 
 
 
 
 
 
Current assets:
 
 
 
 
 
 
Cash and cash equivalents ($1,102 and $235 respectively from VIE)
 $15,787 
 $592 
Accounts receivable, net of allowance for doubtful accounts of $1,404 and $1,260 as of March 31, 2021 and December 31, 2020
  1,755 
  1,821 
Inventories
  4,210 
  3,969 
Prepaid expenses ($135 and $192 respectively from VIE)
  2,141 
  750 
Other current assets ($91 and $741 respectively from VIE)
  323 
  1,551 
Total current assets
  24,216 
  8,683 
 
    
    
Property, plant and equipment, net ($26,440 and $22,628 respectively from VIE)
  113,090 
  109,880 
Operating lease right-of-use assets ($23 and $28 respectively from VIE)
  2,783 
  2,889 
Other assets ($24 and $24 respectively from VIE)
  3,644 
  3,687 
Total assets
 $143,733 
 $125,139 
 
    
    
Liabilities and stockholders' deficit
    
    
Current liabilities:
    
    
Accounts payable  ($6,988 and $6,271 respectively from VIE)
 $17,574 
 $20,739 
Current portion of long term debt
  11,848 
  44,974 
Short term borrowings
  13,559 
  14,541 
Mandatorily redeemable Series B convertible preferred stock
  3,277 
  3,252 
Accrued property taxes
  6,085 
  5,674 
Accrued contingent litigation fees
  6,200 
  6,200 
Current portion of operating lease liability ($10 and $10 respectively from VIE)
  325 
  316 
Current portion of Series A preferred units ($3,000 and $2,015 respectively from VIE)
  3,000 
  2,015 
Other current liabilities ($300 and $129 respectively from VIE)
  4,498 
  4,524 
Total current liabilities
  66,366 
  102,235 
Long term liabilities:
    
    
Senior secured notes and revolving notes
  129,968 
  125,624 
EB-5 notes
  32,500 
  32,500 
Other long term debt
  11,540 
  11,980 
Series A preferred units ($36,293 and $32,022 respectively from VIE)
  36,293 
  32,022 
Operating lease liability ($8 and $11 respectively from VIE)
  2,502 
  2,578 
Other long term liabilities ($77 and $74 respectively from VIE)
  2,931 
  2,944 
Total long term liabilities
  215,734 
  207,648 
 
    
    
Stockholders' deficit:
    
    
Series B convertible preferred stock, $0.001 par value; 7,235 authorized; 1,323 shares issued and outstanding each period, respectively (aggregate liquidation preference of $3,969 for each period respectively)
  1 
  1 
Common stock, $0.001 par value; 40,000 authorized; 29,851 and 22,830 shares issued and outstanding each period, respectively
  30 
  23 
Additional paid-in capital
  157,933 
  93,426 
Accumulated deficit
  (292,192)
  (274,080)
Accumulated other comprehensive loss
  (4,139)
  (4,114)
Total stockholders' deficit
  (138,367)
  (184,744)
Total liabilities and stockholders' deficit
 $143,733 
 $125,139 
 
The accompanying notes are an integral part of the financial statements.
 
 
4
 
 
AEMETIS, INC.
 
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS
(Unaudited, in thousands except for earnings per share)
 
 
 
For the three months
ended March 31,
 
 
 
2021
 
 
2020
 
Revenues
 $42,807 
 $39,480 
Cost of goods sold
  46,415 
  39,913 
Gross loss
  (3,608)
  (433)
 
    
    
Research and development expenses
  23 
  117 
Selling, general and administrative expenses
  5,382 
  3,936 
Operating loss
  (9,013)
  (4,486)
 
    
    
Other (income) expense:
    
    
Interest expense
    
    
Interest rate expense
  5,965 
  5,586 
Debt related fees and amortization expense
  1,215 
  1,290 
Accretion of Series A preferred units
  1,943 
  960 
Other income
  (31)
  (63)
Loss before income taxes
  (18,105)
  (12,259)
Income tax expense (benefit)
  7 
  (207)
Net loss
 $(18,112)
 $(12,052)
 
    
    
Other comprehensive loss
    
    
Foreign currency translation loss
  (25)
  (668)
Comprehensive loss
 $(18,137)
 $(12,720)
 
    
    
Net loss per common share
    
    
Basic
 $(0.69)
 $(0.58)
Diluted
 $(0.69)
 $(0.58)
 
    
    
Weighted average shares outstanding
    
    
Basic
  26,289 
  20,651 
Diluted
  26,289 
  20,651 
 
The accompanying notes are an integral part of the financial statements.
 
 
5
 
 
AEMETIS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
 (Unaudited, in thousands)
 
 
 
For the three months ended March 31,
 
 
 
2021
 
 
2020
 
Operating activities:
 
 
 
 
 
 
Net loss
 $(18,112)
 $(12,052)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
    
    
Share-based compensation
  835 
  310 
Depreciation
  1,386 
  1,090 
Debt related fees and amortization expense
  1,215 
  1,290 
Intangibles and other amortization expense
  12 
  12 
Accretion of Series A preferred units
  1,943 
  960 
Deferred tax benefit
  - 
  (215)
Provision for bad debts
  144 
  - 
Changes in operating assets and liabilities:
    
    
Accounts receivable
  (78)
  384 
Inventories
  (242)
  1,075 
Prepaid expenses
  (1,391)
  (117)
Other assets
  1,363 
  428 
Accounts payable
  (1,795)
  1,074 
Accrued interest expense and fees
  571 
  5,440 
Other liabilities
  76 
  931 
Net cash provided by (used in) operating activities
  (14,073)
  610 
 
    
    
Investing activities:
    
    
Capital expenditures
  (6,560)
  (2,372)
Grant proceeds received for capital expenditures
  1,191 
  - 
Net cash used in investing activities
  (5,369)
  (2,372)
 
    
    
Financing activities:
    
    
Proceeds from borrowings
  - 
  3,780 
Repayments of borrowings
  (31,631)
  (3,645)
Grant proceeds received for capital expenditures
  115 
  - 
Payments on finance leases
  (124)
  - 
Proceeds from issuance of common stock in equity offering
  62,438 
  - 
Proceeds from the exercise of stock options
  1,003 
  - 
Proceeds from Series A preferred units financing
  3,130 
  1,285 
Series A preferred financing redemption
  (300)
  - 
Net cash provided by financing activities
  34,631 
  1,420 
 
    
    
Effect of exchange rate changes on cash and cash equivalents
  6 
  (11)
Net change in cash and cash equivalents for period
  15,195 
  (353)
Cash and cash equivalents at beginning of period
  592 
  656 
Cash and cash equivalents at end of period
 $15,787 
 $303 
 
    
    
Supplemental disclosures of cash flow information, cash paid:
    
    
Cash paid for interest
 $5,296 
 $182 
Income taxes paid
  7 
  8 
Supplemental disclosures of cash flow information, non-cash transactions:
    
    
Subordinated debt extension fees added to debt
  340 
  340 
Fair value of warrants issued to subordinated debt holders
  281 
  93 
TEC debt extension, waiver fees, promissory notes fees added to debt
  1,215 
  29 
Capital expenditures in accounts payable
  4,556 
  2,289 
Capital expenditures purchased on financing
  - 
  5,652 
 
The accompanying notes are an integral part of the financial statements.
 
 
6
 
 
AEMETIS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
(Unaudited, in thousands)
 
 
For the three months ended March 31, 2021
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accumulated Other
 
 
 
 
 
 
Series B Preferred Stock
 
 
Common Stock
 
 
Additional
 
 
Accumulated
 
 
Comprehensive
 
 
`Total Stockholders'
 
Description
 
Shares
 
 
Dollars
 
 
Shares
 
 
Dollars
 
 
Paid-in Capital
 
 
Deficit
 
 
Loss
 
 
deficit
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2020
  1,323 
 $1 
  22,830 
 $23 
 $93,426 
 $(274,080)
 $(4,114)
 $(184,744)
 
    
    
    
    
    
    
    
    
Issuance of common stock
  - 
  - 
  5,682 
  6 
  62,389 
  - 
  - 
  62,395 
Stock options exercised
  - 
  - 
  1,226 
  1 
  1,002 
  - 
  - 
  1,003 
Stock-based compensation
  - 
  - 
  - 
  - 
  835 
  - 
  - 
  835 
Issuance and exercise of warrants
  - 
  - 
  113 
  - 
  281 
  - 
  - 
  281 
Foreign currency translation loss
  - 
  - 
  - 
  - 
  - 
  - 
  (25)
  (25)
Net loss
  - 
  - 
  - 
  - 
  - 
  (18,112)
  - 
  (18,112)
 
    
    
    
    
    
    
    
    
Balance at March 31, 2021
  1,323 
 $1 
  29,851 
 $30 
 $157,933 
 $(292,192)
 $(4,139)
 $(138,367)
 
 
 
For the three months ended March 31, 2020
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accumulated Other
 
 
 
 
 
 
Series B Preferred Stock
 
 
Common Stock
 
 
Additional
 
 
Accumulated
 
 
Comprehensive
 
 
Total Stockholders'
 
Description
 
Shares
 
 
Dollars
 
 
Shares
 
 
Dollars
 
 
Paid-in Capital
 
 
Deficit
 
 
Loss
 
 
deficit
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2019
  1,323 
 $1 
  20,570 
 $21 
 $86,852 
 $(237,421)
 $(3,825)
 $(154,372)
 
    
    
    
    
    
    
    
    
Stock-based compensation
  - 
  - 
  - 
  - 
  310 
  - 
  - 
  310 
Issuance and exercise of warrants
  - 
  - 
  113 
  - 
  93 
  - 
  - 
  93 
Foreign currency translation loss
  - 
  - 
  - 
  - 
  - 
  - 
  (668)
  (668)
Net loss
  - 
  - 
  - 
  - 
  - 
  (12,052)
  - 
  (12,052)
 
    
    
    
    
    
    
    
    
Balance at March 31, 2020
  1,323 
 $1 
  20,683 
 $21 
 $87,255 
 $(249,473)
 $(4,493)
 $(166,689)
 
The accompanying notes are an integral part of the financial statements.
 
 
7
 
 
1.          
Nature of Activities and Summary of Significant Accounting Policies
 
Nature of Activities. Headquartered in Cupertino, California, Aemetis, Inc. (collectively with its subsidiaries on a consolidated basis, “Aemetis,” the “Company,” “we,” “our” or “us”) is an international renewable natural gas, renewable fuels and byproducts company focused on the acquisition, development and commercialization of innovative negative carbon intensity products and technologies that replace traditional petroleum-based products.
 
Founded in 2006, we own and operate a 65 million gallon per year ethanol production facility located in Keyes, California (the “Keyes Plant”). In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains (“WDG”), Distillers Corn Oil (“DCO”), and Condensed Distillers Solubles (“CDS”), all of which are sold to local dairies and feedlots as animal feed. We also own and operate a 50 million gallon per year renewable chemical and advanced fuel production facility (“Kakinada Plant”) on the East Coast of India that produces high quality distilled biodiesel and refined glycerin for customers in India and Europe. We operate a research and development laboratory to develop efficient conversion technologies using waste feedstocks to produce biofuels and biochemicals. Additionally, we own a partially completed plant in Goodland, Kansas (the “Goodland Plant”) through our subsidiary Goodland Advanced Fuels, Inc., (“GAFI”), which was formed to acquire the Goodland Plant. On December 31, 2019 we exercised an option to acquire all capital stock of GAFI for $10 and consolidated assets, liabilities, and equity of GAFI are included as a wholly owned subsidiary from December 31, 2019.
 
We lease a site in Riverbank, California, near the Keyes Plant, where we plan to utilize biomass-to-fuel technology that we have licensed from LanzaTech Technology (“LanzaTech”) and InEnTec Technology (“InEnTec”) to build a cellulosic ethanol production facility (the “Riverbank Cellulosic Ethanol Facility”). By producing ultra-low carbon renewable cellulosic ethanol, we expect to capture higher value D3 RINs and California’s LCFS credits. D3 RINs have a higher value in the marketplace than D6 RINs due to D3 RINs’ relative scarcity and mandated pricing formula from the United States EPA.
 
We also own and operate the Kakinada Plant with a nameplate capacity of 150 thousand metric tons per year, or about 50 million gallons per year. We believe the Kakinada Plant is one of the largest biodiesel production facilities in India on a nameplate capacity basis. The Kakinada Plant is capable of processing a variety of vegetable oils and animal fat waste feedstocks into biodiesel that meet international product standards. The Kakinada Plant also distills the crude glycerin byproduct from the biodiesel refining process into refined glycerin, which is sold to the pharmaceutical, personal care, paint, adhesive and other industries.
 
During 2018, Aemetis Biogas, LLC (“ABGL”) was formed to construct bio-methane anaerobic digesters at local dairies near the Keyes Plant, many of whom also purchase WDG produced at the Keyes Plant. The digesters are connected via a pipeline owned by ABGL to a gas cleanup and compression unit being built at the Keyes Plant to produce Renewable Natural Gas (“RNG”). During the third quarter of 2020, ABGL completed construction on the first two diary digesters along with the pipeline that carries bio-methane from these dairies to the Keyes Plant. Upon receiving the bio-methane from the dairies, impurities are removed, and the bio-methane is converted to RNG where it will be either injected into the local gas utility pipeline, supplied to a renewable compressed natural gas (“RCNG”) truck loading station that will service local trucking fleets, or used as renewable energy at the Keyes Plant.
 
In December 2018, we acquired a 5.2-acre parcel of land for the construction of a gas-to-liquid CO₂ production facility by Messer. Aemetis sells carbon dioxide (“CO₂”) produced at the Keyes Plant (the “CO₂ Project”) to Messer for conversion and sale into the food processing, beverage, and technology sectors. We commenced operations in late April 2020 and started recognizing revenue from this project in the second quarter of 2020.
 
 
8
 
 
On March 18, 2020, in order to address a worldwide shortage of hand sanitizer during the COVID-19 pandemic, the US Treasury Tobacco and Alcohol Tax and Trade Bureau (the “TTB”) provided emergency waivers allowing fuel ethanol plants to produce high-grade alcohol for use in the production of hand sanitizer. Immediately following the emergency waiver for ethanol producers in March, Aemetis began supplying high-grade alcohol for the production of hand sanitizer. During the first week of April 2020, Aemetis applied for and was approved by the TTB as a Distilled Spirits Producer (“DSP”), allowing the Company to produce fuel ethanol, high-grade alcohol for sanitizer, and other health care and sanitary products, as well as industrial alcohol and potable alcohol for beverage spirits.
 
To further address this market, Aemetis began a series of capital projects at the Keyes Plant that will ultimately enable the Company to produce US Pharmacopeia (“USP”) grade alcohol for sale into these key medical, consumer, governmental and industrial alcohol markets. During June 2020, Aemetis renamed Biofuels Marketing, Inc. as Aemetis Health Products, Inc., and began a sales and marketing strategy of blending, bottling, and selling hand sanitizer into bulk, retail branded, and white label markets. Additionally, Aemetis Health Products, Inc. is developing sales and marketing channels for other personal protective equipment.
 
In December 2020, Aemetis Properties Riverbank, Inc., acquired less than a 20% ownership in Nevo Motors, Inc. (“Nevo Motors”). Under this agreement, Nevo Motors will utilize certain of Aemetis’ existing and future manufacturing facilities and fueling stations, as well as renewable natural gas and renewable electricity produced by Aemetis. The investment has been recorded at zero value as of March 31, 2021 and December 31, 2020.
 
During the first quarter of 2021, Aemetis announced its “Carbon Zero” biofuels production plants designed to produce biofuels, including renewable jet and diesel fuel utilizing cellulosic hydrogen and non-edible renewable oils sourced from existing Aemetis biofuels plants and other sources. The first plant, in Riverbank, California, “Carbon Zero 1”, is expected to utilize hydroelectric and other renewable power available onsite to produce 45 million gallons per year of jet fuel, renewable diesel, and other byproducts. The plant is expected to supply the aviation and truck markets with ultra-low carbon renewable fuels to reduce greenhouse gas (“GHG”) emissions and other pollutants associated with conventional petroleum-based fuels.
 
On April 1, 2021, Aemetis established a new subsidiary named Aemetis Carbon Capture, Inc. that is expected to initially capture, dehydrate, compress, and sequester CO₂ from Aemetis Biogas dairy digester projects. Additional capacity for the capture and storage of CO₂ from other carbon emission sources is under development.
 
Basis of Presentation and Consolidation. These consolidated financial statements include the accounts of Aemetis. Additionally, we consolidate all entities in which we have a controlling financial. A controlling financial interest is usually obtained through ownership of a majority of the voting interests. However, an enterprise must consolidate a variable interest entity (“VIE”) if the enterprise is the primary beneficiary of the VIE, even if the enterprise does not own a majority of the voting interests. The primary beneficiary is the party that has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance, and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. ABGL was assessed to be a VIE and through the Company's ownership interest in all of the outstanding common stock, the Company has been determined to be the primary beneficiary and accordingly, the assets, liabilities, and operations of ABGL are consolidated into those of the Company.
 
All intercompany balances and transactions have been eliminated in consolidation.
 
 
9
 
 
The accompanying consolidated condensed balance sheet as of March 31, 2021, the consolidated condensed statements of operations and comprehensive loss for the three months ended March 31, 2021 and 2020, the consolidated condensed statements of cash flows for the three months ended March 31, 2021 and 2020, and the consolidated condensed statements of stockholders’ deficit for the three months ended March 31, 2021 and 2020 are unaudited. The consolidated condensed balance sheet as of December 31, 2020 was derived from the 2020 audited consolidated financial statements and notes thereto. The consolidated condensed financial statements in this report should be read in conjunction with the 2020 audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2020. The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.
 
In the opinion of Company’s management, the unaudited interim consolidated condensed financial statements for the three months ended March 31, 2021 and 2020 have been prepared on the same basis as the audited consolidated statements as of December 31, 2020 and reflect all adjustments, consisting primarily of normal recurring adjustments, necessary for the fair presentation of its statement of financial position, results of operations and cash flows. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the operating results for any subsequent quarter, for the full fiscal year or any future periods.
 
Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, revenues, and expenses during the reporting period. To the extent there are material differences between these estimates and actual results, the Company’s consolidated financial statements will be affected.
 
Revenue Recognition. We derive revenue primarily from sales of ethanol and related co-products in North America, and biodiesel and refined glycerin in India pursuant to supply agreements and purchase order contracts. We assessed the following criteria under the Accounting Standards Codification (“ASC”) 606 guidance: (i) identify the contracts with customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when the entity satisfies the performance obligations.
 
North America:  In North America, until May 13, 2020, we sold all our ethanol to J.D. Heiskell & Co. (“J.D. Heiskell”) under the Working Capital and Purchasing Agreement (the “J.D. Heiskell Purchasing Agreement”). On May 13, 2020, we entered into an amendment to the Corn Procurement and Working Capital Agreement with J.D. Heiskell (the “Corn Procurement and Working Capital”), under the terms of which we buy all corn from J.D. Heiskell and sell all WDG and corn oil we produce to J.D. Heiskell. Following May 13, 2020, we sold the majority of our fuel ethanol production to one customer, Kinergy Marketing, LLC (“Kinergy”), through individual sales transactions. Given the similarity of the individual sales transactions with Kinergy, we have assessed them as a portfolio of similar contracts. The performance obligation is satisfied by delivery of the physical product to one of Kinergy’s contracted trucking companies. Upon delivery, the customer has the ability to direct the use of the product and receive substantially all of its benefits. The transaction price is determined based on daily market prices negotiated by Kinergy for ethanol and by our marketing partner A.L. Gilbert Company (“A.L. Gilbert”) for WDG. There is no transaction price allocation needed.
 
During the first quarter of 2020, Aemetis began selling high-grade alcohol for consumer applications directly to customers on the West Coast and Midwest using a variety of payment terms. These agreements and terms were evaluated according to ASC 606 guidance and such revenue is recognized upon satisfaction of the performance obligation by delivery of the product based on the terms of the agreement. Sales of high-grade alcohol represented less than 3% of quarterly revenue, and as such aggregated with ethanol sales for the three months ended March 31, 2020. The Company had no sales of high-grade alcohol in the three months ended March 31, 2021.
 
 
10
 
 
The below table shows our sales in North America by product category:
 
North America (in thousands)
 
 
 
 
 
 
 
 
 For the three months
ended March 31,
 
 
 
2021
 
 
2020
 
Ethanol and high-grade alcohol sales
 $29,920 
 $25,322 
Wet distiller's grains sales
  11,035 
  8,374 
Other sales
  1,373 
  2,176 
 
 $42,328 
 $35,872 
 
We have elected to adopt the practical expedient that allows for ignoring the significant financing component of a contract when estimating the transaction price when the transfer of promised goods to the customer and customer payment for such goods are expected to be within one year of contract inception. Further, we have elected to adopt the practical expedient in which incremental costs of obtaining a contract are expensed when the amortization period would otherwise be less than one year.
 
We also assessed principal versus agent criteria as we buy our feedstock from our customers and process and sell finished goods to those customers in certain contractual agreements.
 
In North America, we buy corn as feedstock for the production of ethanol, from our working capital partner J.D. Heiskell. Prior to May 13, 2020, we sold all our ethanol, WDG, and corn oil to J.D. Heiskell. Subsequent to May 13, 2020, we sold most of our fuel ethanol to one customer, Kinergy, and sold all WDG and corn oil to J.D. Heiskell. We consider the purchase of corn as a cost of goods sold and the sale of ethanol, upon transfer to the common carrier, as revenue on the basis that (i) we control and bear the risk of gain or loss on the processing of corn which is purchased at market prices into ethanol and (ii) we have legal title to the goods during the processing time. The pricing for both corn and ethanol is set independently. Revenues from sales of ethanol and its co-products are billed net of the related transportation and marketing charges. The transportation component is accounted for in cost of goods sold and the marketing component is accounted for in sales, general and administrative expense. Transportation and marketing charges are known within days of the transaction and are recorded at the actual amounts. The Company has elected an accounting policy under which these charges have been treated as fulfillment activities provided after control has transferred. As a result, these charges are recognized in cost of goods sold and selling, general and administrative expenses, respectively, when revenue is recognized. Revenues are recorded at the gross invoiced amount. Hence, we are the principal in North America sales scenarios where our customer and vendor may be the same.
 
We have a contract liability of $0.2 million as of March 31, 2021 and December 31, 2020, in connection with a contract with a customer to sell carbon credit allowances.
 
India:  In India, we sell products pursuant to purchase orders (written or verbal) or by contract with governmental or international parties, in which performance is satisfied by delivery and acceptance of the physical product. Given that the contracts are sufficiently similar in nature, we have assessed these contracts as a portfolio of similar contracts as allowed under the practical expedient. Doing so does not result in a materially different outcome compared to individually accounting for each contract. All domestic and international deliveries are subject to certain specifications as identified in the contracts. The transaction price is determined daily based on reference market prices for biodiesel, refined glycerin, and PFAD net of taxes. Transaction price allocation is not needed.
 
 
11
 
 
The below table shows our sales in India by product category:
 
India (in thousands)
 
 
 
 
 
 
 
 
 For the three months
ended March 31,
 
 
 
2021
 
 
2020
 
Biodiesel sales
 $358 
 $2,793 
Refined glycerin sales
  116 
  90 
PFAD sales
  - 
  712 
Other sales
  5 
  13 
 
 $479 
 $3,608 
 
In India, we also assessed principal versus agent criteria as we buy our feedstock from our customers and process and sell finished goods to those same customers in certain contractual agreements. In those cases, we receive the legal title to feedstock from our customers once it is on our premises. We control the processing and production of biodiesel based on contract terms and specifications. The pricing for both feedstock and biodiesel is set independently. We hold the title and risk to biodiesel according to agreements when we enter into in these situations. Hence, we are the principal in India sales scenarios where our customer and vendor may be the same.
 
Cost of Goods Sold. Cost of goods sold includes those costs directly associated with the production of revenues, such as raw material consumed, factory overhead and other direct production costs. During periods of idle plant capacity, costs otherwise charged to cost of goods sold are reclassified to selling, general and administrative expense.
 
Accounts Receivable. The Company sells ethanol and WDG through third-party marketing arrangements generally without requiring collateral and high-grade alcohol directly to customers on a variety of terms including advanced payment terms, based on the size and creditworthiness of the customer. DCO is marketed and sold to A.L. Gilbert and other customers under the J.D. Heiskell Purchasing Agreement. The Company sells CDS directly to customers on standard 30 day payment terms. The Company sells biodiesel, glycerin, and processed natural oils to a variety of customers and may require advanced payment based on the size and creditworthiness of the customer. Usually, invoices are due within 30 days on net terms. Accounts receivables consist of product sales made to large creditworthy customers. Trade accounts receivable are presented at original invoice amount, net of any allowance for doubtful accounts.
 
The Company maintains an allowance for doubtful accounts for balances that appear to have specific collection issues. The collection process is based on the age of the invoice and requires attempted contacts with the customer at specified intervals. If, after a specified number of days, the Company has been unsuccessful in its collection efforts, a bad debt allowance is recorded for the balance in question. Delinquent accounts receivables are charged against the allowance for doubtful accounts once un-collectability has been determined. The factors considered in reaching this determination are the apparent financial condition of the customer and the Company’s success in contacting and negotiating with the customer. If the financial condition of the Company’s customers were to deteriorate, additional allowances may be required. We reserved $1.4 million and $1.3 million in the allowances for doubtful accounts as of March 31, 2021 and December 31, 2020, respectively.
 
Inventories. Finished goods, raw materials, and work-in-process inventories are valued using methods which approximate the lower of cost (first-in, first-out) or net realizable value (“NRV”). Distillers’ grains and related products are stated at NRV. In the valuation of inventories, NRV is determined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.
 
 
12
 
 
Investments. The Company follows ASC 325-20, Cost Method Investments, to account for its ownership interest in noncontrolled entities. Under ASC 325-20, equity securities that do not have readily determinable fair values (i.e., non-marketable equity securities) and are not required to be accounted for under the equity method are typically carried at cost (i.e., cost method investments). Investments of this nature are initially recorded at cost. Income is recorded for dividends received that are distributed from net accumulated earnings of the noncontrolled entity subsequent to the date of investment. Dividends received in excess of earnings subsequent to the date of investment are considered a return of investment and are recorded as reductions in the cost of the investment. Investments are written down only when there is clear evidence that a decline in value that is other than temporary has occurred. During 2020, the Company received 489,716 preferred stock shares and 5,000,000 common stock shares in Nevo Motors, a privately held company, in exchange for conversion of its existing debt, carried at zero value, into equity. Due to the lack of operations, the carrying amount of our investment is zero at March 31, 2021 and December 31, 2020.
 
Variable Interest Entities. We determine at the inception of each arrangement whether an entity in which we have made an investment or in which we have other variable interests in is considered a variable interest entity (“VIE”). We consolidate VIEs when we are the primary beneficiary. The primary beneficiary of a VIE is the party that meets both of the following criteria: (1) has the power to make decisions that most significantly affect the economic performance of the VIE; and (2) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Periodically, we assess whether any changes in our interest or relationship with the entity affect our determination of whether the entity is still a VIE and, if so, whether we are the primary beneficiary. If we are not the primary beneficiary in a VIE, we account for the investment or other variable interests in a VIE in accordance with applicable GAAP.
 
Property, Plant and Equipment. Property, plant, and equipment are carried at cost less accumulated depreciation after assets are placed in service and are comprised primarily of buildings, furniture, machinery, equipment, land, biogas dairy digesters, and the Keyes Plant, Goodland Plant and Kakinada Plant. The Goodland Plant is partially completed and is not ready for operation. The first two dairy digesters and pipeline in the Biogas Project were completed, commissioned and began to be depreciated during the third quarter of 2020. The CO₂ Project was completed and commenced operations in the second quarter of 2020. Accordingly, any assets under the CO₂ Project began being depreciated starting in May 2020. It is the Company’s policy to depreciate capital assets over their estimated useful lives using the straight-line method.
 
The Company evaluates the recoverability of long-lived assets with finite lives in accordance with ASC Subtopic 360-10-35 Property Plant and Equipment—Subsequent Measurements, which requires recognition of impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, based on estimated undiscounted cash flows, the impairment loss would be measured as the difference between the carrying amount of the assets and its estimated fair value. The Company has not recorded any impairment during the three months ended March 31, 2021 and 2020.
 
California Energy Commission Low-Carbon Fuel Production Program. The Company has been awarded $4.2 million in matching grants from the California Energy Commission Low-Carbon Fuel Production Program (“LCFPP”). The LCFPP grant reimburses the Company for costs to design, procure, and install processing facility to clean-up, measure and verify negative-carbon intensity dairy renewable natural gas fuel at the production facility in Keyes, California. The Company has received $875 thousand from the LCFPP as of March 31, 2021 as reimbursement for actual costs incurred. Due to the uncertainty associated with the approval process under the grant program, the Company recognizes the grant as a reduction of the costs in the period when approval is received. 
 
 
13
 
 
California Department of Food and Agriculture Dairy Digester Research and Development Grant. The Company has been awarded $3.2 million in matching grants from the California Department of Food and Agriculture (“CDFA”) Dairy Digester Research and Development program. The CDFA grant reimburses the Company for costs required to permit and construct two of the Company’s biogas capture systems under contract with central California dairies. The Company received $3.2 million as of March 31, 2021 as reimbursement for actual costs incurred. Due to the uncertainty associated with the approval process under the grant program, the Company recognizes the grant as a reduction of the costs in the period when approval is received.
 
California Energy Commission Low Carbon Advanced Ethanol Grant Program. In May 2019, the Company was awarded the right to receive reimbursements from the California Energy Commission Community-Scale and Commercial-Scale Advanced Biofuels Production Facilities grant under the Alternative and Renewable Fuel and Vehicle Technology Program in an amount up to $5.0 million (the “CEC Reimbursement Program”) in connection with the Company’s expenditures toward the development of the Riverbank Cellulosic Ethanol Facility. To comply with the guidelines of the CEC Reimbursement Program, the Company must make a minimum of $7.9 million in matching contributions to the Riverbank Project. The Company receives funds under the CEC Reimbursement Program for actual expenses incurred up to $5.0 million as long as the Company makes the minimum matching contribution. Given that the Company has not made the minimum matching contribution, the grant for reimbursement of capital expenditures of $115 thousand received during the first quarter of 2021, and $1.7 million from prior years were recorded as other long term liabilities as of March 31, 2021. Due to the uncertainty associated with meeting the minimum matching contribution, the reimbursement will be recognized when the Company makes the minimum matching contribution.
 
Basic and Diluted Net Loss per Share. Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share reflects the dilution of common stock equivalents such as options, convertible preferred stock, debt, and warrants to the extent the impact is dilutive. As the Company incurred net losses for the three months ended March 31, 2021 and 2020, potentially dilutive securities have been excluded from the diluted net loss per share computations as their effect would be anti-dilutive.
 
The following table shows the number of potentially dilutive shares excluded from the diluted net loss per share calculation as of March 31, 2021 and 2020:
 
 
 
As of
 
 
 
March 31,
2021
 
 
March 31,
2020
 
 
 
 
 
 
 
 
Series B preferred (post split basis)
  132 
  132 
Common stock options and warrants
  5,080 
  5,688 
Debt with conversion feature at $30 per share of common stock
  1,286 
  1,269 
 
    
    
Total number of potentially dilutive shares excluded from the diluted loss per share calculation
  6,498 
  7,089 
 
Comprehensive Loss. ASC 220 Comprehensive Income requires that an enterprise report, by major components and as a single total, the change in its net assets from non-owner sources. The Company’s other comprehensive loss and accumulated other comprehensive loss consists solely of cumulative currency translation adjustments resulting from the translation of the financial statements of its foreign subsidiary. The investment in this subsidiary is considered indefinitely invested overseas, and as a result, deferred income taxes are not recorded related to the currency translation adjustments.
 
 
14
 
 
Foreign Currency Translation/Transactions. Assets and liabilities of the Company’s non-U.S. subsidiary that operates in a local currency environment, where that local currency is the functional currency, are translated into U.S. dollars at exchange rates in effect at the balance sheet date and the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Income and expense accounts are translated at average exchange rates during the year. Transactional gains and losses from foreign currency transactions are recorded in other (income) loss, net.
 
Operating Segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Aemetis recognized two reportable geographic segments: “North America” and “India.”
 
The “North America” operating segment includes the Company’s 65 million gallons per year capacity Keyes Plant in California, the cellulosic ethanol facility in Riverbank, the cluster of biogas digesters on dairies near Keyes, California, the Goodland Plant, Kansas and the research and development facility in Minnesota.
 
The “India” operating segment includes the Company’s 50 million gallon per year capacity Kakinada Plant in India, the administrative offices in Hyderabad, India, and the holding companies in Nevada and Mauritius.
 
Fair Value of Financial Instruments. Financial instruments include accounts receivable, accounts payable, accrued liabilities, current and non-current portion of subordinated debt, notes receivable, notes payable, series A preferred units, and long-term debt.  Due to the unique terms of our notes payable and long-term debt and the financial condition of the Company, the fair value of the debt is not readily determinable.  The fair value, determined using level 3 inputs, of all other current financial instruments is estimated to approximate carrying value due to the short-term nature of these instruments.
 
Share-Based Compensation. The Company recognizes share-based compensation expense in accordance with ASC 718 Stock Compensation requiring the Company to recognize expenses related to the estimated fair value of the Company’s share-based compensation awards at the time the awards are granted, adjusted to reflect only those shares that are expected to vest.
 
Commitments and Contingencies. The Company records and/or discloses commitments and contingencies in accordance with ASC 450 Contingencies. ASC 450 applies to an existing condition, situation or set of circumstances involving uncertainty as to possible loss that will ultimately be resolved when one or more future events occur or fail to occur.
 
Convertible Instruments. The Company evaluates the impacts of convertible instruments based on the underlying conversion features. Convertible instruments are evaluated for treatment as derivatives that could be bifurcated and recorded separately. Any beneficial conversion feature is recorded based on the intrinsic value difference at the commitment date.
 
Debt Modification Accounting. The Company evaluates amendments to its debt in accordance with ASC 470-50 Debt–Modification and Extinguishments for modification and extinguishment accounting. This evaluation includes comparing the net present value of cash flows of the new debt to the old debt to determine if changes greater than 10 percent occurred. In instances where the net present value of future cash flows changed more than 10 percent, the Company applies extinguishment accounting and determines the fair value of its debt based on factors available to the Company.
 
 
15
 
 
Recently Issued Accounting Pronouncements.
 
ASU 2016-13: Measurement of Credit Losses on Financial Instruments. This ASU requires the use of an expected loss model for certain types of financial instruments and requires consideration of a broader range of reasonable and supportable information to calculate credit loss estimates. For trade receivables, loans and held-to-maturity debt securities, an estimate of lifetime expected credit losses is required. For available-for-sale debt securities, an allowance for credit losses will be required rather than a reduction to the carrying value of the asset. This standard is effective for fiscal years beginning after December 15, 2022. We are assessing the impact of adopting this standard on our consolidated financial statements and related disclosures.
 
For a complete summary of the Company’s significant accounting policies, please refer to the Company’s audited financial statements and notes thereto for the years ended December 31, 2020 and 2019 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2021.
 
2.            
Inventories
 
Inventories consist of the following:
 
 
 
As of
 
 
 
March 31,
2021
 
 
December 31,
2020
 
Raw materials
 $1,321 
 $1,382 
Work-in-progress
  1,938 
  1,266 
Finished goods
  951 
  1,321 
Total inventories
 $4,210 
 $3,969 
 
As of March 31, 2021 and December 31, 2020, the Company recognized a lower of cost or market impairment of $0.1 million and $0.7 million respectively, related to inventory.
 
3.          
Property, Plant and Equipment
 
Property, plant and equipment consist of the following:
 
 
 
As of
 
 
 
March 31,
2021
 
 
December 31,
2020
 
Land
 $4,091 
 $4,092 
Plant and buildings
  97,249 
  97,398 
Furniture and fixtures
  1,191 
  1,195 
Machinery and equipment
  5,272 
  5,188 
Construction in progress
  30,032 
  25,397 
Property held for development
  15,408 
  15,408 
Finance lease right of use assets
  2,308 
  2,308 
Total gross property, plant & equipment
  155,551 
  150,986 
Less accumulated depreciation
  (42,461)
  (41,106)
Total net property, plant & equipment
 $113,090 
 $109,880 
 
For the three months ended March 31, 2021 and 2020, interest capitalized in property, plant, and equipment was $0.6 and $0.1 million, respectively.
 
 
16
 
 
Construction in progress contains incurred costs for the Biogas Project, Riverbank Project, and Zebrex equipment installation at the Keyes Plant. In the second quarter of 2020, CO₂ Project commenced operations and was placed in service at that time.  In the third quarter of 2020, two diary digesters commenced operations and were placed in service at that time. Given there are several ongoing capital projects, their capital expenses have been accumulated in construction in progress and will be capitalized and depreciated once the capital projects are finished and are in service. Depreciation on the components of property, plant and equipment is calculated using the straight-line method over their estimated useful lives as follows:
 
 
Years
Plant and buildings
 
20 - 30
Machinery and equipment
 
5 - 15
Furniture and fixtures
 
3 - 5
 
For the three months ended March 31, 2021 and 2020, the Company recorded depreciation expense of $1.4 and $1.1 million, respectively.
 
Management is required to evaluate these long-lived assets for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. Management determined there was no impairment on the long-lived assets during the three months ended March 31, 2021 and 2020.
 
4.          
Debt
 
Debt consists of the following:
 
 
 
March 31,
2021
 
 
December 31,
2020
 
Third Eye Capital term notes
 $7,095 
 $7,066 
Third Eye Capital revolving credit facility
  85,105 
  80,310 
Third Eye Capital revenue participation term notes
  11,913 
  11,864 
Third Eye Capital acquisition term notes
  26,463 
  26,384 
Third Eye Capital promissory note
  - 
  1,444 
Cilion shareholder seller notes payable
  6,311 
  6,274 
Subordinated notes
  12,973 
  12,745 
Term loan on Equipment purchase
  5,652 
  5,652 
EB-5 promissory notes
  42,769 
  43,120 
PPP loans
  1,134 
  1,134 
GAFI Term and Revolving loans
  - 
  33,626 
Total debt
  199,415 
  229,619 
Less current portion of debt
  25,407 
  59,515 
Total long term debt
 $174,008 
 $170,104 
 
 
17
 
 
Third Eye Capital Note Purchase Agreement
 
On July 6, 2012, Aemetis, Inc. and Aemetis Advanced Fuels Keyes, Inc. (“AAFK”), entered into an Amended and Restated Note Purchase Agreement with Third Eye Capital (the “Note Purchase Agreement”). Pursuant to the Note Purchase Agreement, Third Eye Capital extended credit in the form of (i) senior secured term loans in an aggregate principal amount of approximately $7.2 million to replace existing notes held by Third Eye Capital (the “Term Notes”); (ii) senior secured revolving loans in an aggregate principal amount of $18.0 million (the “Revolving Credit Facility”); (iii) senior secured term loans in the principal amount of $10.0 million to convert the prior revenue participation agreement to a note (the “Revenue Participation Term Notes”); and (iv) senior secured term loans in an aggregate principal amount of $15.0 million (the “Acquisition Term Notes”) used to fund the cash portion of the acquisition of Cilion, Inc. (the Term Notes, Revolving Credit Facility, Revenue Participation Term Notes and Acquisition Term Notes are referred to herein collectively as the “Original Third Eye Capital Notes”).
 
On April 1, 2020, the Company exercised the option to extend the maturity of Third Eye Capital Notes to April 1, 2021 for a fee of 1% of the outstanding note balance instead of agreed fee of 5% in Amendment No.14 to the Note Purchase Agreement. We have evaluated the reduction in extension fee to 1% in accordance with ASC 470-60 Troubled Debt Restructuring. According to the guidance, we considered the 1% extension fee to be a troubled debt restructuring.
 
On August 11, 2020, Third Eye Capital agreed to Limited Waiver and Amendment No. 17 to the Note Purchase Agreement (“Amendment No. 17”), to (i) provide that the maturity date of the Third Eye Capital Notes may be further extended at our election to April 1, 2022 in exchange for an extension fee equal to 1% of the Note Indebtedness in respect to each Note, provided that such fee may be added to the outstanding principal balance of each Note on the effective date of each such extension, (ii) provide for a waiver of the ratio of note indebtedness covenant for the quarters ended March 31, 2021 and June 30, 2021. As consideration for such amendment and waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.3 million in cash (the “Amendment No. 17 Fee”). On November 5, 2020, Third Eye Capital agreed to Limited Waiver and Amendment No. 18 to the Note Purchase Agreement (“Amendment No. 18”) to provide for a waiver of the ratio of note indebtedness covenant for the quarter ended September 30, 2021. As consideration for such amendment and waivers, the borrowers also agreed to pay Third Eye Capital an amendment fee of $50 thousand. We have evaluated the 1% extension fee in Amendment No. 17, and the $50 thousand waiver fee in Amendment No. 18 in accordance with ASC 470-60 Troubled Debt Restructuring.
 
According to the guidance, we considered the 1% extension fee in Amendment No.17 and the $50 thousand waiver fee in Amendment No. 18 to be troubled debt restructurings. In order to assess whether the creditor granted a concession, we calculated the post-restructuring effective interest rate by projecting cash flows on the new terms and calculated a discount rate equal to the carrying amount of pre-restructuring of debt, and by comparing this calculation to the terms of Amendment No. 15, we determined that Third Eye Capital provided a concession in accordance with the provisions of ASC 470-60 and thus applied troubled debt restructuring accounting, resulting in no gain or loss from the application of this accounting. Using the effective interest method of amortization, the 1% extension fee of $1.0 million and Amendment No. 17 Fee of $0.3 million are being amortized over the stated remaining life of the Third Eye Capital Notes.
 
On February 27, 2019, a promissory note (the “February 2019 Note”, together with the Original Third Eye Capital Notes, the “Third Eye Capital Notes”) for $2.1 million was advanced by Third Eye Capital to Aemetis, Inc., as a short-term credit facility for working capital and other general corporate purposes with an interest rate of 14% per annum maturing on the earlier of (a) receipt of proceeds from any financing, refinancing, or other similar transaction, (b) extension of credit by payee, as lender or as agent on behalf of certain lenders, to the Company or its affiliates, or (c) April 30, 2019. In consideration of the February 2019 Note, $0.1 million of the total proceeds were paid to Third Eye Capital as financing charges. On April 30, 2019, the February 2019 Note was modified to remove the stated maturity date and instead be due on demand by Third Eye Capital. In third quarter of 2019, the February 2019 Note was modified to include additional borrowings of $0.7 million. In first quarter of 2020, the February 2019 Note was modified to include additional borrowings of $0.6 million. The February 2019 note was fully repaid in the first quarter of 2021.
 
 
18
 
 
On March 14, 2021, Third Eye Capital agreed to Limited Waiver and Amendment No. 19 to the Note Purchase Agreement (“Amendment No. 19”), to (i) provide for a waiver of the ratio of note indebtedness covenant for the quarter ended December 31, 2021, (ii) provide for a waiver of the consolidated unfunded capital expenditures covenant for the quarters through March 31, 2021. As consideration for such amendment and waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.1 million in cash (the “Amendment No. 19 Fee”). We gave the notice to extend the maturity date of the Notes to April 1, 2022 and the extension fee equal to 1% of the Note Indebtedness in respect to each Note, provided that half of such fee may be added to the outstanding principal balance of each Note on the effective date of each such extension and rest of the balance may be payable in cash or common stock within 60 days of the date of such relevant extension. We evaluated the terms of the Amendment No. 19 and the maturity date extension and applied modification accounting treatment in accordance with ASC 470-50 Debt – Modification and Extinguishment.
 
Based on prior amendments and Amendment No. 19, the ratio of note indebtedness covenant is waived for the quarters ended June 30, 2021 through December 31, 2021. In addition, the ratio of note indebtedness covenant is increased from 70% to 100% in the Amendment No. 19 effective March 31, 2022. According to ASC 470-10-45 Debt -Other Presentation Matters, if it is probable that the Company will not be able to cure the default at measurement dates within the next 12 months, the related debt needs to be classified as current. To assess this guidance, the Company performed ratio and cash flow analysis using its cash flow forecast and debt levels. The Company forecasted sufficient cash flows over the next 12 months to reduce debt levels of Third Eye Capital and meet operations of the Company. Based on this analysis, the Company believes that it is not probable that through a combination of cash flows from operations, sales from EB-5 investments, and proceeds from the sale of common stock, it will not be able to meet the ratio of the note indebtedness covenant over the next 12 months. As such, the notes are classified as long-term debt.
 
On March 6, 2020, we and a subsidiary entered into a one-year reserve liquidity facility governed by a promissory note, payable to Third Eye Capital, in the principal amount of $18 million. We do not currently expect to draw upon the note. However, we determined that it was prudent to maintain a liquidity reserve in case of unforeseen needs. Borrowings under the facility are available from March 6, 2020 until maturity on April 1, 2021. Interest on borrowed amounts accrues at a rate of 30% per annum, paid monthly in arrears, or 40% if an event of default has occurred and continues. The outstanding principal balance of the indebtedness evidenced by the promissory note, plus any accrued but unpaid interest and any other sums due thereunder, shall be due and payable in full at the earlier to occur of (a) the closing of any new debt or equity financing, refinancing or other similar transaction between Third Eye Capital or any fund or entity arranged by them and the Company or its affiliates, (b) receipt by the Company or its affiliates of proceeds from any sale, merger, equity or debt financing, refinancing or other similar transaction from any third party and (c) April 1, 2021. The promissory note is secured by liens and security interests upon the property and assets of the Company as described in that certain Amended and Restated Note Purchase Agreement, dated as of July 6, 2012. If any amounts are drawn under the facility, the Company will pay a non-refundable fee in the amount of $500,000, payable from the proceeds of the first drawing under the facility.
 
On March 14, 2021, Third Eye agreed to increase the amount available under the Liquidity facility to $70.0 million and extend the maturity date to April 1, 2022. Borrowings under the facility are available from March 14, 2021 until maturity on April 1, 2022. Interest on borrowed amounts accrues at a rate of 30% per annum, paid monthly in arrears and may be capitalized and due upon maturity, or 40% if an event of default has occurred and continues. The outstanding principal balance of the indebtedness evidenced by the promissory note, plus any accrued but unpaid interest and any other sums due thereunder, shall be due and payable in full at the earlier to occur of (a) receipt by the Company or its affiliates of proceeds from any sale, merger, equity or debt financing, refinancing or other similar transaction from any third party and (b) April 1, 2022. Any amounts may be re-borrowed up to repaid amounts up until the maturity date of April 1, 2022. The promissory note is secured by liens and security interests upon the property and assets of the Company. In return, the Company will pay a non-refundable standby fee at 2% per annum of the difference between the aggregate principal amount outstanding and the commitment, payable monthly in cash. In addition, if any initial advances are drawn under the facility, the Company will pay a non-refundable one-time fee in the amount of $0.5 million provided that such fee may be added to the principal amount of the promissory note on the date of such initial advance.
 
Terms of Third Eye Capital Notes
 
A. 
Term Notes. As of March 31, 2021, the Company had $7.1 million in principal and interest outstanding net of $71 thousand unamortized debt issuance costs under the Term Notes. The Term Notes accrue interest at 14% per annum. The Term Notes mature on April 1, 2022. Fifty percent of the extension fee is due by May 31, 2021 and can be paid in cash or stock, hence $35 thousand was included as part of current portion of long term debt at March 31, 2021.
 
 
19
 
 
B 
Revolving Credit Facility. The Revolving Credit Facility accrues interest at the prime rate plus 13.75% (17.00% as of March 31, 2021) payable monthly in arrears. The Revolving Credit Facility matures on April 1, 2022. As of March 31, 2021, AAFK had $85.1 million in principal and interest and waiver fees outstanding net of $926 thousand unamortized debt issuance costs under the Revolving Credit Facility. Fifty percent of the extension fee is due by May 31, 2021 and can be paid in cash or stock, hence $418 thousand was included as part of current portion of long term debt at March 31, 2021.
 
C. 
Revenue Participation Term Notes. The Revenue Participation Term Note bears interest at 5% per annum and matures on April 1, 2022. As of March 31, 2021, AAFK had $11.9 million in principal and interest outstanding net of $119 thousand unamortized debt issuance costs on the Revenue Participation Term Notes. Fifty percent of the extension fee is due by May 31, 2021 and can be paid in cash or stock, hence $60 thousand was included as part of current portion of long term debt at March 31, 2021.
 
D. 
Acquisition Term Notes. The Acquisition Term Notes accrue interest at the prime rate plus 10.75% (14.00% per annum as of March 31, 2021) and mature on April 1, 2022. As of March 31, 2021, Aemetis Facility Keyes, Inc. had $26.4 million in principal and interest and redemption fees outstanding net of $191 thousand unamortized debt issuance costs. The outstanding principal balance includes a total of $7.5 million in redemption fees. Fifty percent of the extension fee is due by May 31, 2021 and can be paid in cash or stock, hence $95 thousand was included as part of current portion of long term debt at March 31, 2021.
 
E. 
Reserve Liquidity Notes. The Reserve Liquidity Notes, with available borrowing capacity in the amount of $70.0 million, accrues interest at the rate of 30% per annum and are due and payable upon the earlier of receipt by the Company or its affiliates of proceeds from any sale, merger, equity or debt financing, refinancing or other similar transaction from any third party and April 1, 2022. We have no borrowings outstanding under the Reserve Liquidity Notes as of March 31, 2021.
 
The Third Eye Capital Notes contain various covenants, including but not limited to, debt to plant value ratio, minimum production requirements, and restrictions on capital expenditures. The terms of the Third Eye Capital Notes allow the lender to accelerate the maturity in the occurrence of any event that could reasonably be expected to have a material adverse effect, such as any change in the business, operations, or financial condition. The terms of the notes allow interest to be capitalized.
 
The Third Eye Capital Notes are secured by first priority liens on all real and personal property of, and assignment of proceeds from all government grants and guarantees from the Company’s North American subsidiaries. The Third Eye Capital Notes all contain cross-collateral and cross-default provisions. McAfee Capital, LLC (“McAfee Capital”), owned by Eric McAfee, the Company’s Chairman and CEO, provided a guaranty of payment and performance secured by all of its Company shares. In addition, Eric McAfee provided a blanket lien on substantially all of his personal assets, and McAfee Capital provided a guarantee in the amount of $8.0 million.
 
Cilion shareholder seller notes payable. In connection with the Company’s merger with Cilion, Inc., (“Cilion”) on July 6, 2012, the Company issued $5.0 million in notes payable to Cilion shareholders as merger compensation subordinated to the senior secured Third Eye Capital Notes. The liability bears interest at 3% per annum and is due and payable after the Third Eye Capital Notes have been paid in full. As of March 31, 2021, Aemetis Facility Keyes, Inc. had $6.3 million in principal and interest outstanding under the Cilion shareholder seller notes payable.
 
 
20
 
 
Subordinated Notes. On January 6 and January 9, 2012, AAFK entered into Note and Warrant Purchase Agreements with two accredited investors pursuant to which it issued $0.9 million and $2.5 million in original notes to the investors (“Subordinated Notes”). The Subordinated Notes mature every six months. Upon maturity, the Subordinated Notes are generally extended with a fee of 10% added to the balance outstanding plus issuance of warrants exercisable at $0.01 with a two-year term. Interest accrues at 10% and is due at maturity. Neither AAFK nor Aemetis may make any principal payments under the Subordinated Notes until all loans made by Third Eye Capital to AAFK are paid in full.
 
The Subordinated Notes were amended to extend the maturity date on January 1, 2020 and again on July 1, 2020 with six months extension for maturity until December 31, 2020. We evaluated these amendments and the refinancing terms of the notes and applied modification accounting treatment in accordance with ASC 470-50 Debt – Modification and Extinguishment.
 
On January 1, 2021, the Subordinated Notes were amended to extend the maturity date until the earlier of (i) June 30, 2021; (ii) completion of an equity financing by AAFK or Aemetis, Inc. in an amount of not less than $25.0 million; or (iii) after the occurrence of an Event of Default, including failure to pay interest or principal when due and breaches of note covenants. A 10% cash extension fee was paid by adding the fee to the balance of the new note and warrants to purchase 113 thousand shares of common stock were granted with a term of two years and an exercise price of $0.01 per share. We evaluated the January 1, 2021 amendment and the refinancing terms of the notes and applied modification accounting treatment in accordance with ASC 470-50 Debt – Modification and Extinguishment.
 
At March 31, 2021 and December 31, 2020, the Company had, in aggregate, the amount of $13.0 million and $12.7 million in principal and interest outstanding, respectively, net of $324 thousand and none of unamortized debt issuance costs, respectively, under the Subordinated Notes.
 
EB-5 promissory notes. EB-5 is a U.S. government program authorized by the Immigration and Nationality Act designed to foster employment-based visa preference for immigrant investors to encourage the flow of capital into the U.S. economy and to promote employment of U.S. workers. The Company entered into a Note Purchase Agreement dated March 4, 2011 (as further amended on January 19, 2012 and July 24, 2012) with Advanced BioEnergy, LP, a California limited partnership authorized as a “Regional Center” to receive EB-5 investments, for the issuance of up to 72 subordinated convertible promissory notes (the “EB-5 Notes”) bearing interest at 2-3%. Each note was issued in the principal amount of $0.5 million and due and payable four years from the date of each note, for a total aggregate principal amount of up to $36.0 million (the “EB-5 Phase I funding”). The original maturity date on the promissory notes can be extended automatically for a one- or two-year period initially and is eligible for further one-year automatic extensions as long as there is no notice of non-extension from investors and the investors’ immigration process is in progress. On February 27, 2019, Advanced BioEnergy, LP, and the Company entered into an Amendment to the EB-5 Notes which restated the original maturity date on the promissory notes with automatic six-month extensions as long as the investors’ immigration processes are in progress. Except for six early investor EB-5 Notes, the Company was granted 12 months from the date of the completion of immigration process to redeem these EB-5 Notes. Accordingly, the notes have been recognized as long-term debt while the six early investor notes and several investors who obtained green card approval have been classified as current debt. The EB-5 Notes are convertible after three years at a conversion price of $30 per share. 
 
Advanced BioEnergy, LP arranges investments with foreign investors, who each make loans to the Keyes Plant in increments of $0.5 million. The Company has sold an aggregate principal amount of $36.0 million of EB-5 Notes under the EB-5 Phase I funding since 2012 to the date of this filing. As of March 31, 2021, $35.5 million has been released from the escrow amount to the Company, with $0.5 million remaining to be funded to escrow. As of March 31, 2021, the Company paid principal amount of one of the EB-5 investors who obtained the green card approval under the program. As of March 31, 2021, $35.0 million in principal and $3.6 million in accrued interest was outstanding on the EB-5 Notes sold under the EB-5 Phase I funding.
 
 
21
 
 
On October 16, 2016, the Company launched its EB-5 Phase II funding, with plans to issue $50.0 million in additional EB-5 Notes on substantially similar terms and conditions as those issued under the Company’s EB-5 Phase I funding, to refinance indebtedness and capital expenditures of Aemetis, Inc. and GAFI (the “EB-5 Phase II funding”). On November 21, 2019, the minimum investment was raised from $0.5 million per investor to $0.9 million per investor. The Company entered into a Note Purchase Agreement dated with Advanced BioEnergy II, LP, a California limited partnership authorized as a Regional Center to receive EB-5 Phase II funding investments, for the issuance of up to 100 EB-5 Notes bearing interest at 3%. On May 1, 2020 Supplement No. 3 amended the offering documents and lowered the total eligible new EB-5 Phase II funding investors to 60. Eight EB-5 investors have funded at the $0.5 million per investor amount, so 52 new EB-5 Phase II funding investors are eligible at the new $0.9 million per investor amount under the current offering. Job creation studies show it may be possible to add additional investors and increase the total offering amount in the future. Each new note will be issued in the principal amount of $0.9 million and due and payable five years from the date of each note, for a total aggregate principal amount of up to $50.8 million.
 
Advanced BioEnergy II, LP arranges investments with foreign investors, who each make loans to the Riverbank Cellulosic Ethanol Facility in increments of $0.9 million after November 21, 2019. The Company has sold an aggregate principal amount of $4.0 million of EB-5 Notes under the EB-5 Phase II funding since 2016 to the date of this filing. As of March 31, 2021, $4.0 million has been released from escrow to the Company and $46.8 million remains to be funded to escrow. As of March 31, 2021, $4.2 million was outstanding on the EB-5 Notes under the EB-5 Phase II funding.
 
Unsecured working capital loans. On April 16, 2017, the Company entered into an operating agreement with Gemini Edibles and Fats India Private Limited (“Gemini”). Under this agreement, Gemini agreed to provide the Company with working capital, on an as needed basis, to fund the purchase of feedstock and other raw materials for the Kakinada Plant. Working capital cash advances bear interest at 12% and working capital can be induced through trading of feedstock or finished goods by Gemini, which does not have any interest accrual. In return, the Company agreed to pay Gemini an amount equal to 30% of the plant’s monthly net operating profit and recognized these as operational support charges in the financials. In the event that the Company’s biodiesel facility operates at a loss, Gemini owes the Company 30% of the losses as operational support charges. Either party can terminate the agreement at any time without penalty. Additionally, Gemini received a first priority lien on the assets of the Kakinada Plant. During the three months ended March 31, 2021 and 2020, we have accrued no interest on Gemini. During the three months ended March 31, 2021 and 2020, the Company made principal payments to Gemini of none and approximately $3.6 million, respectively. As of March 31, 2021 and December 31, 2020, the Company had no outstanding balance under this agreement.
 
In November 2008, the Company entered into an operating agreement with Secunderabad Oils Limited (“Secunderabad Oils”). The 2008 agreement provided the working capital and had the first priority lien on assets in return for 30% of the plant’s monthly net operating profit. These expenses were recognized as selling, general, and administrative expenses by the Company in the financials. All terms of the 2008 agreement with Secunderabad Oils were terminated to amend the agreement as below. On July 15, 2017, the agreement with Secunderabad Oils was amended to provide the working capital funds for British Petroleum business operations only in the form of inter-corporate deposit for an amount of approximately $2.3 million over a 95 day period at the rate of 14.75% per annum interest rate. The term of the agreement continues until either party terminates it. Secunderabad Oils has a second priority lien on the assets of the Company’s Kakinada Plant after this agreement. On April 15, 2018, the agreement was amended to purchase the raw material for business operations at 12% per annum interest rate. During the three months ended March 31, 2021 and 2020, the Company made principal and interest payments to Secunderabad Oils of none and approximately $34 thousand, respectively. As of March 31, 2021 and December 31, 2020 the Company had no outstanding balance under this agreement.
 
 
22
 
 
GAFI Term loan and Revolving loan. On July 10, 2017, GAFI entered into a Note Purchase Agreement (“Note Purchase Agreement”) with Third Eye Capital. See further discussion regarding GAFI in Note 6. Pursuant to the Note Purchase Agreement, Third Eye Capital agreed, subject to the terms and conditions of the Note Purchase Agreement and relying on each of the representations and warranties set forth therein, to make (i) a single term loan to GAFI in an aggregate amount of $15 million (“Term Loan”) and (ii) revolving advances not to exceed $10 million dollars in the aggregate (the “Revolving Loans”). The interest rate applicable to the Term Loan is equal to 10% per annum. The interest rate applicable to the Revolving Loans is the greater of prime rate plus 7.75% and 12.00% per annum. The maturity date of the loans was extended to July 10, 2021 by exercising an option to extend the GAFI Loan Maturity Date for a fee of $0.5 million.
 
On June 28, 2018, GAFI entered into Amendment No. 1 to the GAFI Term Loan with Third Eye Capital for an additional amount of $1.5 million with a fee of $75 thousand added to the loan from Third Eye Capital at a 10% interest rate. On December 20, 2018, $1.6 million from Amendment No. 1 was repaid. Pursuant to Amendment No. 1, Aemetis, Inc. entered into a Stock Appreciation Rights Agreement to issue 1,050,000 Stock Appreciation Rights (“SARs”) to Third Eye Capital on August 23, 2018, with an exercise date of one year from the issuance date with a call option for the Company at $2.00 per share during the first 11 months of the agreement either to pay $2.1 million in cash or issue common stock worth $2.1 million based on the 30-day weighted average price of the stock on the call date, and a put option for Third Eye Capital at $1.00 per share during the 11th month of the agreement where the Company can redeem the SARs for $1.1 million in cash. In the event that none of the above options is exercised, the SARs will be automatically exercised one year from the issuance date based upon the 30-day weighted average stock price and paid in cash and cash equivalents. On July 22, 2019, Third Eye Capital exercised the put option at $1.00 per share for $1.1 million. The exercise value of the SARs of $1.1 million was added to the GAFI Term Loan and the SARs fair value liability was released.
 
The Company fully repaid the GAFI notes in the first quarter of 2021. As of March 31, 2021 and December 31, 2020, GAFI had none and $22.2 million net of debt issuance costs of none and $0.4 million outstanding on the Term Loan and none and $11.8 million on the Revolving Loan respectively, classified as current portion of long-term debt.
 
Payroll Protection Program. On May 5, 2020, certain wholly owned subsidiaries of the Company received loan proceeds of approximately $1.1 million; (“PPP Loans”) under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides loans to qualifying businesses for payroll expenses of the qualifying business. The PPP Loan and accrued interest are forgivable after 24 weeks if the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the 24 week period. In order to obtain full or partial forgiveness of the PPP Loan, the Company must request forgiveness and must provide satisfactory documentation in accordance with applicable Small Business Administration (“SBA”) guidelines. The Company is in process for applying for forgiveness.
 
The PPP Loans are evidenced by promissory notes, dated May 1, 2020 and April 30, 2020 (the “Notes”), between the Company, as borrower, and Bank of America, N.A., as lender (the “PPP Lender”). The interest rate on the Note is 1.00% per annum. No payments of principal or interest are due during the six-month period beginning on the funding date (the “Deferral Period”). If the SBA does not confirm forgiveness or only partly confirms forgiveness of the PPP Loans, or Borrower fails to apply for loan forgiveness, the Company will be obligated to repay to the PPP Lender the total outstanding balance remaining due under the PPP Loans, including principal and interest and in such case, the PPP Lender will establish the terms for repayment of the PPP Loans in a separate letter to be provided to the Company in which the letter will set forth the loan balance, the amount of each monthly payment, the interest rate (not in excess of a fixed rate of 1.00% per annum, the term of the PPP Loans, and the maturity date, which, if not established by the PPP Lender, shall be two years from the funding date of the PPP Loans.
 
 
23
 
 
Financing Agreement for Equipment Purchase. The Company entered into an agreement with Mitsubishi Chemical America, Inc. (“Mitsubishi”) to purchase certain equipment to save energy used in the Keyes Plant. We also entered into a financing agreement with the Mitsubishi for $5.7 million for this equipment. Payments pursuant to the financing transaction will commence after the installation date and interest will be charged based on the certain performance metrics after operation of the equipment. The equipment was delivered in March 2020; however, the installation has been delayed due to the COVID-19 pandemic. Hence, we recorded the asset in property, plant and equipment, net and the related liability of $0.6 million in short term borrowings and $5.1 million in other long term debt, respectively as of March 31, 2021.
 
Scheduled debt repayments for the Company’s loan obligations follow:
 
Twelve months ended March 31,
 
Debt Repayments
 
2022
 $25,407 
2023
  160,624 
2024
  7,936 
2025
  4,496 
2026
  936 
There after
  1,324 
Total debt
  200,723 
Debt issuance costs
  (1,308)
Total debt, net of debt issuance costs
 $199,415 
 
5. Commitments and Contingencies
 
Leases
 
We have identified assets as the corporate office, warehouse, monitoring equipment and laboratory facilities over which we have control and obtain economic benefits fully. We classified these identified assets as operating leases after assessing the terms under classification guidance. We have entered into several leases for trailers and carbon units with purchase option at the end of the term. We have concluded that it is reasonably certain that we would exercise the purchase option at the end of the term, hence the leases were classified as finance leases. All of our leases have remaining term of less than a year to 8 years.
 
When discount rates implicit in leases cannot be readily determined, the Company uses the applicable incremental borrowing rate at lease commencement to perform lease classification tests on lease components and measure lease liabilities and right-of-use (“ROU”) assets. The incremental borrowing rate used by the Company was based on weighted average baseline rates commensurate with the Company’s secured borrowing rate over a similar term. At each reporting period, when there is a new lease initiated, the rates established for that quarter will be used.
 
 
24
 
 
The components of lease expense and sublease income was as follows:
 
 
 
Three Months ended March 31,
 
 
 
2021
 
 
2020
 
Operating lease cost
 
 
 
 
 
 
Operating lease expense
 $204 
 $177 
Short term lease expense
  39 
  14 
Variable lease expense
  33 
  34 
Total operating lease cost
 $276 
 $225 
 
    
    
Finance lease cost
    
    
Amortization of right-of-use assets
 $55 
 $- 
   Interest on lease liabilities
  21 
  - 
Total finance lease cost
 $76 
 $- 
 
Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
Three Months ended March 31,
 
 
 
2021
 
 
2020
 
 Operating cash flows used in operating leases
 $167 
 $179 
 Operating cash flows used in finance leases
  21 
  - 
 Financing cash flows used in finance leases
 $124 
  - 
 
Supplemental non-cash flow information related to ROU asset and lease liabilities was as follows for the three months ended March 31, 2021 and March 31, 2020:
 
 
 
Three Months ended March 31,
 
 
 
2021
 
 
2020
 
Operating leases
 
 
 
 
 
 
      Accretion of the lease liability
 $99 
 $17 
      Amortization of right-of-use assets
  105 
  160 
 
    
    
Weighted Average Remaining Lease Term
    
    
   Operating leases
    
 
6.7 years
 
   Finance leases
    
 
3.0 years
 
 
    
    
Weighted Average Discount Rate
    
    
 Operating leases
    
  14.0%
 Finance leases
    
  5.5%
 
 
25
 
 
Supplemental balance sheet information related to leases was as follows:
 
 
 
As of
 
 
 
March 31,
2021
 
 
December 31,
2020
 
Operating leases
 
 
 
 
 
 
Operating lease right-of-use assets
 $2,783 
 $2,889 
 
    
    
Current portion of operating lease liability
  325 
  316 
Long term operating lease liability
  2,502 
  2,578 
Total operating lease liabilities
  2,827 
  2,894 
 
    
    
Finance leases
    
    
Property and equipment, at cost
 $2,204 
 $2,308 
Accumulated depreciation
  (200)
  (249)
  Property and equipment, net
  2,004 
  2,059 
 
    
    
   Other current liability
  422 
  417 
 Other long term liabilities
  1,057 
  1,164 
Total finance lease liabilities
  1,479 
  1,581 
 
Maturities of operating le